Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
| 198.1 | |
| 193.7 | |
| - | |
| 198.1 | |
| 193.7 | |
| 87-198.1 | |
| 5 587 M | |
| 96.6915 | |
| 28 558 K | |
| 95 949 K | |
| -1.25 | |
| 0.836 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a tren...
Amid a backdrop of rising markets with the Dow Jones Industrial Average reaching new heights, the U.S. stock market continues to display resilience and optimism. In such an environment, growth compani...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
